Cas:146924-94-9 3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one manufacturer & supplier

Chemical Name:3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one

CAS.NO:146924-94-9

Synonyms:3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one

Molecular Formula:C₁₆H₁₅NO₃

Molecular Weight:269.29500

HS Code:

Physical and Chemical Properties:

Melting point:196-197ºC

Boiling point:551.3ºC at 760 mmHg

Density:1.295

Index of Refraction:1.637

PSA:49.77000

Exact Mass:269.10500

LogP:2.20900

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one Use and application,3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one technical grade,usp/ep/jp grade.

Related News: Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one manufacturer Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one supplier Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one vendor The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” 3-hydroxy-1-(4-methoxyphenyl)-4-phenylazetidin-2-one factory Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data.